# Study of Efficacy and Safety of CTL019 in Adult ALL Patients

> **NCT02167360** · PHASE2 · WITHDRAWN · sponsor: **Abramson Cancer Center at Penn Medicine**

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Relapsed B-cell Acute Lymphoblastic Leukemia
- Refractory B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** CTL019

## Key facts

- **NCT ID:** NCT02167360
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-06
- **Primary completion:** 2017-01-11
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Did not enroll
- **Last updated:** 2017-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02167360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02167360, "Study of Efficacy and Safety of CTL019 in Adult ALL Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02167360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*